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Abstract
Background: Radiation recall gastritis is rare but can be induced after concurrent chemoradiation for pancreatic
cancer. We report a patient with pancreatic cancer who developed radiation-recall gastritis related to a combination
of gemcitabine and erlotinib.
Case presentation: A 54-year-old female with unresectable pancreatic cancer received gemcitabine in combination
with radiation therapy followed by chemotherapy with gemcitabine and erlotinib. After completing 2 cycles
of chemotherapy, the patient had epigastric pain, nausea, and vomiting. Abdominal computed tomography
(CT) scan revealed diffuse wall thickening of the stomach, and esophagogastroduodenoscopy (EGD) showed
multiple gastric ulcers. The patient was treated with proton pump inhibitors (PPI) and was continued on maintenance
chemotherapy. Two months later, the patient presented with the similar symptoms and persistent gastric ulcers were
observed during subsequent EGD. Nevertheless, the patient’s symptom had resolved with PPI therapy. Thus,
the patient underwent maintenance chemotherapy with gemcitabine and erlotinib for additional 4 cycles.
Eventually, follow-up abdominal CT Scan and EGD at 6 months demonstrated resolution of the gastric ulcers.
Conclusions: Physicians should be aware of the possibility of radiation recall gastritis associated with a combination
of gemcitabine and erlotinib. Administration of PPIs may mitigate the adverse effects of gemcitabine and erlotinib in
the presence of radiation recall gastritis; however further studies are warranted.
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Background
Radiation recall is known as chemotherapy-triggered in-
flammatory reaction in previously exposed areas to ir-
radiation but the mechanism is poorly understood [1].
Radiation recall gastritis can be occurred in pancreatic
cancer [2]. Radiation recall gastritis due to combination
of gemcitabine and erlotinib has not been reported in
the literature. There are only two case reports, one is
gemcitabine-related and the other is erlotinib-associated
radiation recall gastritis [2, 3].
We experienced a case of pancreatic cancer with radi-
ation recall gastritis after combination therapy of gemci-
tabine and erlotinib, but exhibited gradual improvement
along with proper maintenance the combination chemo-
therapy and PPI (proton pump inhibitor).
Case presentation
A 54-year-old woman with no medical history presented
with a complaint of periumbilical pain and weight loss.
Physical examination indicated tenderness in the epigas-
trium. Her initial blood tests showed hemoglobin level,
13.4 g/dL; white blood cell count, 5600/μL; platelet
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count, 281000/μL; and levels of amylase, 48 U/L; lipase,
61 U/L; CA 19-9, 605 U/mL; and CEA, 1.2 ng/mL.
Abdominal computed tomography (CT) and magnetic
resonance imaging revealed a 3.5 cm, pancreatic mass
abutting the celiac axis, splenic vein, and superior mes-
enteric artery. There was also hypermetabolic left in-
guinal lymphadenopathy. She was diagnosed with stage
T4N1M0.
The patient was initially treated with concurrent radio-
therapy (total of 50.0 Gy) and chemotherapy of gemcita-
bine (600 mg/m2 weekly for 5 weeks). The patient was
then treated with gemcitabine and erlotinib. Gemcita-
bine was administered at a dose of 1000 mg/m2/week
for 3 weeks every 4 weeks, and erlotinib (dosed 100 mg
once daily) was administered without cessation. After
2 cycles of chemotherapy, the patient visited the emer-
gency room (ER) for epigastric pain, nausea, and vomit-
ing. Abdominal CT scan showed a substantial decrease
in the size of the pancreatic mass from 3.5 cm to 2.0 cm,
but also revealed diffuse thickening of stomach wall
(Fig. 1). The patient underwent an esophagogastroduo-
denoscopy (EGD). Initial endoscopic findings revealed
multiple, deep active ulcers in the gastric antrum
(Fig. 2a-b), and microscopic examination of gastric bi-
opsy specimens showed chronic gastritis. The patient
discharged on anti-ulcer medication including a PPI.
Two months later, she revisited ER with the same symp-
toms and gastric ulcers still were observed on subse-
quent EGD. The patient’s symptom had relieved with
symptomatic care. Therefore, she received 4 additional
cycles of maintenance chemotherapy with gemcitabine
and erlotinib and did not have any other side effects
with chemotherapy. On the 6-month follow-up
examinations, abdominal CT revealed improved thicken-
ing of the gastric wall and EGD showed improvement of
the gastric ulcers (Figs. 3; 4a-b).
Discussion
Radiation recall phenomenon is now a well-recognized
phenomenon since radiation recall dermatitis was re-
ported in 1975 [4]. Radiation recall dermatitis has been
reported most frequently with a frequency of 8.8 % and
characterized by an inflammatory reaction within a pre-
viously irradiated skin after administration of antineopla-
tic drugs [5].
Antineoplastic drugs have mainly been involved in ra-
diation recall reactions. Most common anticancer agents
that cause radiation recall reactions are the anthracycline
doxorubicin, the taxanes docetaxel and paclitaxel, and
the antimetabolites gemcitabine and capecitabine [1].
Fig. 1 CT shows diffuse low density wall thickening of stomach
Fig. 2 EGD. a Several medium sized active ulcers on diffuse, edematous
and thickened wall of gastric antrum. b Diffuse edematous mucosal
swelling on gastric body
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Although there are several pathophysiological theories
concerning radiation recall, the most accepted hypoth-
esis is the drug hypersensitivity reaction. In this hypoth-
esis, radiation lowers the inflammatory response
threshold and induces the expression of certain cyto-
kines, and then the drug triggers a non-immune inflam-
matory reaction [1].
Gemcitabine induced radiation recall was reported in
the skin, central nervous system, musculoskeletal
systems and gastrointestinal tract. The time between
initiation of radiation and recall of the radiation
phenomenon ranged from 3 weeks to 8 months from
the initiation of gemcitabine [6].
Dermatitis and pneumonitis were reported as the
radiation recall reactions associated with erlotinib [7].
Recently there was a report of gastrointestinal bleed-
ing secondary to radiation recall gastritis related to
erlotinib [3]. The mechanism of erlotinib-induced ra-
diation recall gastritis is also unclear, but Graziani et
al. [3] suggested the association between the patho-
genesis of radiation recall and erlotinib’s up-regulation
of the angiogenic growth factor thymidine phosphor-
ylase. Erlotinib, as an orally administered epidermal
growth factor receptor (EGFR) tyrosine kinase inhibi-
tor, can cause gastrointestinal ulcer without relation
with radiation because EGFR is highly expressed in
the epithelium of the gastrointestinal tract. However,
this case showed ulcers and prominent wall thicken-
ing only in gastric antrum and body, confined to pre-
viously irradiated area. To our knowledge, this report
is the first case of radiation recall gastritis due to
combination of gemcitabine and erlotinib. It could be
assumed that the combination therapy could result in
a higher radiation recall incidence.
Radiation recall reactions have been reported in the
literature, but management remains controversial
whether or not to continue the drug, especially chemo-
therapeutic agent. Suggested management of the recall
reaction is discontinuing drug and initiating steroid
therapy, supportive therapy, and/or nonsteroidal anti-
inflammatory agents [6]. There were two reports treated
with discontinuing drug in radiation gastritis associated
with gemcitabine and erlotinib [2, 3]. Meanwhile there is
a partial support for the continuation of chemotherapy
even when a recall reaction is encountered [8]. In this
case, diffuse gastritis and ulcers were treated with PPI
and the patient eventually recovered from the radiation
recall gastritis without discontinuation of chemotherapy.
It can be assumed that recovery was partly due to re-
duced absorption of erlotinib because absorption of
Fig. 3 Followed CT scan shows improvement of wall thickening
of stomach
Fig. 4 a, b Followed EGD shows improvement of ulcers and
wall thickening
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erlotinib is known to be pH dependent. However Ter
Heine et al. [9] reported that trough concentrations of
erlotinib were not diminished when PPI was adminis-
tered orally. More studies are needed on the role of PPI
in radiation gastritis.
Conclusions
This is the first case report of radiation recall gastritis
due to combination of gemcitabine and erlotinib. It
could be followed with proton pump inhibitor during
chemotherapy without withdrawal.
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